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Background: Several factors are associated with an increased risk of preterm birth (PTB); therefore, various
interventions might have the potential to influence it. Due to the large number of interventions that address PTB,
the objective of this overview is to summarise evidence from Cochrane reviews regarding the effects and safety of
these different interventions.
Methods: We conducted a systematic literature search in the Cochrane Database of Systematic Reviews.
Included reviews should be based on randomised controlled trials comparing antenatal non-pharmacological
and pharmacological interventions that directly or indirectly address PTB with placebo/no treatment or routine care
in pregnant women at less than 37 completed weeks of gestation without signs of threatened preterm labour. We
considered PTB at less than 37 completed weeks of gestation as the primary outcome.
Results: We included 56 Cochrane systematic reviews. Three interventions increased PTB risk significantly. Twelve
interventions led to a statistically significant lower incidence of PTBs. However, this reduction was mostly observed in
defined at-risk subgroups of pregnant women. The remaining antenatal interventions failed to prove a significant effect
on PTB < 37 weeks, but some of them at least showed a positive effect in secondary outcomes (e.g., reduction in early
PTBs). As an unintended result of this review, we identified 28 additional Cochrane reviews which intended to report
on PTB < 37 weeks, but were not able to find any RCTs reporting appropriate data.
Conclusions: The possible effects of a diverse range of interventions on PTB have been evaluated in Cochrane
systematic reviews. Few interventions have been demonstrated to be effective and a small number have been found
to be harmful. For around half of the interventions evaluated, the Cochrane review concluded that there was
insufficient evidence to provide sound recommendations for clinical practice. No RCT evidence is available for a
number of potentially relevant interventions.
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Preterm birth (PTB) is defined as childbirth occurring at
less than 37 completed weeks of gestation [1]. PTB is a
major determinant of neonatal mortality and morbidity,
and has long-term, adverse consequences for health (e.g.,
learning disabilities or visual and hearing problems). On
average, 12% of babies are born too soon in the poorest
countries, compared with 9% in higher-income countries
[2]. In almost all countries with reliable data, PTB rates
are increasing. Possible reasons for this include increases
in maternal age and underlying maternal health problems* Correspondence: brigitte.piso@hta.lbg.ac.at
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reproduction in any medium, provided the orsuch as diabetes and hypertensive disorders, as well as iat-
rogenic factors like greater use of infertility treatments
leading to increased rates of multiple pregnancies, and
changes in obstetric practices such as more caesarean
births before term [2].
PTB is a multi-factorial disorder. A wide spectrum of
predisposing factors is associated with PTB [3,4]: There
is a genetic influence and PTB rates differ across ethnic
groups. Social stress and maternal factors (e.g., smoking,
alcohol consumption, poor nutritional status, advanced ma-
ternal age) and several non-genital tract infections have also
been shown to be associated with increased risk of PTB.
Last but not least, intrauterine infection may contribute to. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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of the PTB cases are unknown.
Due to the number of different factors that might con-
tribute to an increased PTB risk, several interventions
might have the potential to influence it. According to a
summary published in 2008 [5] on interventions which
might be able to influence PTB risk, primary preventive
measures like protein and calorie supplementation, cal-
cium, vitamin C or E supplementation, as well as periodon-
tal care failed to prove beneficial effects on PTB in
randomised controlled trials. Among the screening mea-
sures for low-risk women, screening for and treatment of
asymptomatic bacteriuria had been reported to reduce the
PTB rate, while other screening and subsequent treatment
measures (e.g., for/of ureaplasma urealyticum, group B
streptococcus, trichomonas vaginalis and fetal fibronectin
testing with subsequent metronidazole and erythromycin
treatment) did not reduce PTBs. Among secondary pre-
ventive measures targeted at women with known risk fac-
tors for PTB, only low-dose aspirin had shown a reduction
in PTBs for women with risk of pre-eclampsia, while cal-
cium supplementation did not alter PTB rates, and antioxi-
dants even showed an increased risk for PTB. Effects of
bed rest, limited work and reduced sexual activity for
women with increased PTB risk had not been researched
at all. Omega-3 supplements had shown a significant PTB
reduction in women at risk of PTB, while more intensive
antenatal care had failed to prove significant effects on
PTB. Though antibiotic treatment of bacterial vaginosis
had preliminarily shown positive effects in subgroups of
women with increased PTB risk, other trials displayed con-
flicting results (even an increase in PTBs for metronidazole
treatment). Progesterone had been beneficial in some at-
risk populations, while cerclage had shown a reduction in
PTBs in women with a short cervix and a history of previ-
ous PTB, no reduction in women with a short cervix with-
out a history of previous PTB, and an increase in women
with twin pregnancy. Besides these primary and secondary
preventive measures during pregnancy, preconceptional in-
terventions for all women of reproductive age, as well as
interventions targeted at women with immediate PTB risk,
have been discussed as influencing actual PTB rates.
Given the large number of Cochrane reviews that address
primary and secondary preventive antenatal interventions
that might be able to modify PTB incidence, the objective
of this overview is to summarise evidence from Cochrane
reviews regarding their effects and safety. Hence, we pur-
sued the following research question: In pregnant women
at less than 37 completed weeks of gestation without signs
of threatened preterm labour do non-pharmacological or
pharmacological preventive, therapeutic or screening inter-
ventions, compared to no treatment, placebo or routine
care (as stated by review authors), reduce the rate of pre-
term births prior to 37 completed weeks of gestation?Methods
Literature search
We conducted a systematic literature search in the
Cochrane Database of Systematic Reviews on the 28th
of August 2012. The search strategy is elucidated in
Additional file 1. We also searched in references of in-
cluded reviews and on the Cochrane Library website
for further reviews. We neither searched for reviews
other than Cochrane systematic reviews and any pri-
mary research studies, nor did we contact any review
or single trial author. Two overview authors independ-
ently assessed all the potential systematic reviews. Any
disagreement was resolved through discussion or, if re-
quired, we consulted a third person.
Eligibility criteria for considering reviews for inclusion
We included any published Cochrane systematic review of
(individual or cluster) randomised controlled trials focusing
on primary or secondary preventive antenatal interventions
to directly or indirectly reduce PTBs. The participants in
the reviews considered are pregnant women at less than 37
completed weeks of gestation without signs of threatened
preterm labour (premature labour, premature rupture of
membranes). These women include those of different risk
groups for PTB or underlying conditions. If the population
considered in the review also comprised women in preterm
labour, we only extracted data of subgroup analyses for
women without (threatened) preterm labour.
We included reviews that compared interventions with
placebo/no treatment or ‘routine care’ (as defined by trial-
ists). We included reviews of trials that analysed interven-
tions used in various settings (inpatient, outpatient, home-
based). As far as possible, we focused on interventions
that were mainly studied in high-income countries, but
we did not exclude reviews based on studies carried out in
mixed populations (high- and low-income countries).
We excluded Cochrane reviews analysing effects of pre-
conceptional care, tertiary prevention of PTB and treat-
ments of diseases either uncommon in high-income
countries or without apparent relation to PTB (for example,
HIV, sickle cell anaemia or tuberculosis). We further ex-
cluded Cochrane reviews that exclusively compared differ-
ent treatments or different regimens of one treatment (e.g.,
by dose or route of administration), or that reported effects
of inevitable treatments for morbidities in pregnancy (e.g.,
eclampsia, gonorrhoea). Finally, we excluded Cochrane
reviews that were not able to report on PTB rates due to
the lack of primary research data or if the reviews’ findings
were solely based on RCTs included in a more recent
review.
Types of outcome measures
We defined PTB less than 37 weeks of gestation as the pri-
mary outcome. Therefore, in this overview we only included
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mature birth’, ‘gestational age at birth’ or ‘preterm labour’) as
a predefined outcome.
As secondary outcomes; we analysed whether very pre-
term birth (PTB less than 34 to32 weeks), low birth weight
(LBW, birth weight less than 2500 grams), small for gesta-
tional age (SGA, birth weight below the 10th percentile of
gestational age), admissions to neonatal intensive care units
(NICU, also defined in some reviews as ‘specialised neo-
natal care units’), stillbirths, miscarriages/perinatal deaths
or complications due to interventions for mother or child
(as defined by trialists) were influenced by the interven-
tion in a statistically significant manner.
Assessment of the methodological quality of included
reviews
We did not reassess the eligibility criteria for inclusion
of RCTs in the systematic reviews or the risk of bias of
included primary research studies.
Due to Cochrane’s publishing policy (all systematic re-
views have to follow methods according to the Cochrane
Handbook of Systematic Reviews of Interventions [6]), we
also refrained from a quality assessment of the included
Cochrane reviews.
Data extraction and management
A single researcher extracted the data from the reviews
using a predefined data extraction form. A second re-
searcher independently double-checked the data for cor-
rectness and completeness.
Data synthesis
Because of the heterogeneity of interventions and the re-
search design, we did not perform a meta-analysis to es-
timate a pooled effect size of results. Therefore, our
findings are solely presented descriptively. We list the
review characteristics in [see Additional file 2: Table S2].
For the main outcome – the effect estimations of inter-
ventions on PTB prior to 37 weeks of gestation – we
have provided Additional file 3: Table S1, which include
forest plots of pooled effect sizes reported in the single
systematic reviews. For risk/odds ratios, including the
95% confidence intervals and an overview of the statis-
tical significance of secondary outcomes, see [Additional
file 4: Table S3].
We structured the presentation of results based on the
following classification: First, we provide information on
effects of various antenatal interventions from Cochrane
reviews that primarily intended to report on the impact
on preterm delivery (reviews entitled ‘preventing pre-
term birth/ delivery/miscarriage/labour’, Additional file
3: Table S1a). Under the heading ‘Ultrasound screening’
(Additional file 3: Table S1b), we present results of
Cochrane reviews analysing the effects of ultrasoundscreening in pregnancy. In Additional file 3: Table S1c
(‘Prevention, detection and management of infection’)
we summarise results of Cochrane reviews for infection
screenings and antimicrobial treatments. In Additional
file 3: Table S1d (‘Prevention, detection and management
of hypertension/ pre-eclampsia and hyperglycaemia/
[gestational] diabetes’) we present results of Cochrane
reviews that primarily analysed various interventions
with respect to effects on the mentioned conditions.
Additional file 3: Table S1e (‘Nutritional supplements
and dietary interventions’) provides information about
effects on PTB of diverse supplements as well as other
changes in dietary composition (of reviews entitled ‘in/
during/for pregnancy’; Additional file 3: Table S1e).
Additional file 3: Table S1f (‘Psychological interventions
and alternative models of care’) summarises results of
Cochrane reviews on organisational aspects of antenatal
care. Finally, in Additional file 3: Table S1g (‘Prevention
and management of other morbidities’) we summarise
effects of various interventions that could not be allo-
cated to one of the above mentioned categories (e.g.,




The systematic literature search yielded 559 publica-
tions. After adding hand search results and subsequent
de-duplication, we screened 606 citations on the abstract
level and finally assessed 126 full text articles for eligibil-
ity. Of these, we included 56 Cochrane systematic re-
views that met the inclusion criteria for this overview
(Figure 1).
Characteristics of included reviews
13 reviews addressed mechanical [7] or pharmaceutical
prevention of PTB or miscarriage [8-12], the impact of
other interventions targeted at influencing PTB or miscar-
riage [13-15], or analysed screening/risk assessment inter-
ventions to predict PTB risk and improve pregnancy
outcomes [16-19]; two reviews analysed the effect of
ultrasound screening on pregnancy outcomes [20,21]
(Additional file 3: Table S1b). Seven reviews either
addressed the prevention [22,23], the detection [24] or the
treatment of infection [25-28] (Additional file 3: Table S1c).
Twelve reviews analysed effects of various interventions
applied for the prevention [29-36] or the treatment [37-40]
of hypertensive disorders/pre-eclampsia; one review
focused on interventions for pregnant women with
hyperglycaemia [41] (Additional file 3: Table S1d). Eleven
reviews covered general effects of dietary interventions on
pregnancy outcomes [42-52] (Additional file 3: Table S1e).
Four reviews analysed the effects of providing additional
support [53] or of alternative models of care [54-56]
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Figure 1 Literature selection process (PRISMA flow diagram).
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addressed the prevention or management of other
morbidities [57-62] (Additional file 3: Table S1g).
There was a great difference in the number of in-
cluded RCTs (1–71) and women (45–25740). Diversity
was also seen in the target population of the reviews (e.g.,
all pregnant women, women at risk of PTB or other
predefined risk factors, women with or without a
defined pre-existing morbidity, or women with multiple
pregnancies). 18 reviews are based on trials all published
before the year 2000. On the other hand, three reviews
only included trials published within the last twelve
years. The widest range of the publishing period is
covered by the review on vitamin A supplementation
in pregnancy (1931 to 2010) [44]. A more detailed
description of the reviews’ characteristics can be found in
[see Additional file 2: Table S2].
Effects of interventions
a) Prevention of PTB or miscarriage and detection of PTB risk
Three interventions (cerclage with or without bed rest in
women with singleton pregnancies at high risk of preg-
nancy loss [7], administration of progesterone in women
with previous spontaneous PTB [8] and knowledge of
fetal fibronectin test (FFT) [18]) showed a statistically
significant PTB reduction, while one intervention (di-
ethylstilbestrol supplementation) increased PTB risk [10]
(Additional file 3: Table S1a). Additional positive effectsin secondary outcomes were seen for cerclage [7] and pro-
gesterone [8], which also led to a decrease in early PTBs
[7,8] and reduced perinatal deaths [7] or LBW babies [8],
respectively. Home uterine monitoring in women at risk
of PTB decreased early PTBs and admissions to NICUs
[19]. On the other hand, the negative effect of oestrogen
supplementation on the primary outcome was also seen in
an increase of early PTBs, perinatal deaths and side effects
due to treatment [10]. Without altering any other out-
come significantly, the administration of any vitamins led
to an increase in side effects [13]. No differences in any –
primary or secondary – outcome were observed for the
remaining seven interventions [9,11,12,14-17].
b) Ultrasound screening
None of the reviews [20,21] reported significant group
differences for primary (Additional file 3: Table S1b) or
secondary outcomes.
c) Prevention, detection and management of infection
The review on lower genital tract screening of women
without symptoms of lower genital tract infection found
a decrease in PTBs <37 weeks compared to no screening
[24], whereas metronidazole for the treatment of tricho-
moniasis led to an increase in PTBs compared to no
treatment in asymptomatic women [28] (Additional file
3: Table S1c).With regard to secondary outcomes, lower
genital tract screening [24] and antibiotic treatment of
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LBW babies. No effects in primary or secondary out-
comes were seen for the remaining four interventions
[22,23,25,26].
d) Prevention, detection and management of hypertension/
pre-eclampsia and management of hyperglycaemia
Antiplatelet agents versus none for primary prevention
of pre-eclampsia in women at risk of developing pre-
eclampsia [32], routine calcium supplementation in
pregnancy [35], and some rest in hospital versus routine
activity at home for women with raised blood pressure
[39] showed a significant reduction in PTBs <37 weeks
(Additional file 3: Table S1d).
The only positive effect in secondary outcomes could be
observed for antiplatelet agents in the primary prevention
of pre-eclampsia in women at risk of developing pre-
eclampsia [32], which decreased the incidence of SGA ba-
bies. A negative effect in secondary outcomes – an in-
crease in side-effects – was seen for nitric oxide [30],
diuretics [31], antioxidants [34] and any anti-hypertensive
drugs [37]. The latter effect could not be observed in the
specific analysis of oral beta-blockers for women with mild
to moderate hypertension, but in this comparison the
intervention group was more likely to give birth to SGA
babies [38]. No statistically significant group differences in
primary or secondary outcomes were reported for the
remaining five interventions [29,33,36,40,41].
e) Nutritional supplements and dietary interventions
Significant PTB reductions had been achieved by nutri-
tional advice during pregnancy to increase energy and
protein intake [43], zinc [47], as well as magnesium [48]
supplementation, whereas vitamin C supplementation led
to an increase in PTBs [45] (Additional file 3: Table S1e).
An additional effect in secondary outcomes was seen for
magnesium supplementation, which also decreased the in-
cidence of LBW and SGA babies [48]. A positive effect
solely in secondary outcomes was seen for a balanced pro-
tein/energy supplementation (decrease in SGA babies and
stillbirths) [43], multiple micronutrient supplementation
(decrease of LBW and SGA babies) [50], and marine oil
(reduction of early PTBs, but concurrently increasing side
effects like belching and an unpleasant taste) [51]. Two re-
views reported negative effects in secondary outcomes:
High protein supplementation in pregnancy led to an in-
crease in SGA babies [43], and daily iron supplementation
[49] elevated side effects. No statistically significant group
differences were observed for the remaining four interven-
tions [42,44,46,52].
f) Psychosocial interventions and alternative models of care
None of the four interventions [53-56] reported significant
changes in PTBs <37 weeks (Additional file 3: Table S1f).The only statistically significant effect in secondary out-
comes was seen for the comparison of a reduced number
of antenatal care visits with standard antenatal care pro-
grammes for women at low risk of developing compli-
cations during pregnancy in low- and middle-income
settings (increase of miscarriages/perinatal deaths) [55].
g) Prevention and management of other morbidities
Interventions to promote smoking cessation led to a sig-
nificant decrease in PTBs <37 weeks compared to usual
care [58]. The treatment of hypothyroidism in pregnancy
with levothyroxine versus no treatment also reduced
PTBs <37 weeks, while this positive effect could not be
observed for selenomethionine [61] (Additional file 3:
Table S1g). An additional positive effect in secondary
outcomes was only seen for smoking cessation interven-
tions that also decreased LBWs [58]. Heparin in women
considered at risk of placental dysfunction reduced the
incidence of SGA babies [57] without altering any other
outcome. No effect on primary or secondary outcomes
was seen for the remaining three interventions [59,60,62].
Discussion
Principal findings
This overview of 56 Cochrane systematic reviews primar-
ily analysed the effects of antenatal interventions on PTB
before 37 weeks of gestation. Three interventions in-
creased PTB rates significantly, while twelve interventions
led to a statistically significant lower incidence of PTBs
compared to controls. The remaining interventions failed
to demonstrate a significant effect on PTB rates.
Interventions which increased PTB risk
The three interventions shown in Cochrane reviews to in-
crease PTB incidence were metronidazole treatment in
pregnant women with asymptomatic trichomoniasis [28],
as well as vitamin C [45] or oestrogen [10] supplementa-
tion. Due to various additional negative effects, the latter
is no longer in use.
Interventions which decreased PTB risk
Of the twelve interventions that led to a statistically sig-
nificant lower incidence of PTBs compared to controls,
some observations currently seem to rely on weak evi-
dence due to single, small or poor methodological quality
trials (e.g., fetal fibronectin testing [18], bed rest for hyper-
tension during pregnancy [39] and dietary magnesium
supplementation[48]). The Cochrane review of antenatal
lower genital tract infection screening [24] found a de-
crease of PTBs and LBW babies (based on a single clinical
trial), whereas the previously published review assessing
the effect of antibiotics for the treatment of bacterial
vaginosis [25] was not able to detect group differences.
The remaining eight interventions showed a significant
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The strongest evidence exists for smoking cessation pro-
grammes [58] which have been shown to reduce PTB
rates and LBW babies, as well as the treatment of clinical
hypothyroidism in pregnancy with levothyroxine [61],
which is already standard practice. Concerning cerclage,
Alfirevic et al. [7] found a statistically significant benefit in
PTB reduction compared to no cerclage in women at high
risk of pregnancy loss. This effect might be explained by
adding seven more recent trials compared to the excluded,
older review by Drakeley et al. [63], which had not been
able to prove beneficial effects on PTB. The non-
significant review result for progesterone application by
Meher et al. [29] seems to be contradictory to the signifi-
cant PTB reduction in Dodd et al. [8]. However, Meher
et al. [29] aimed at primarily analysing effects of progester-
one administration on pre-eclampsia prevention. It is
based on a single study with 168 women from the United
States of America who were considered to be at risk of
PTB due to active military service. The significant PTB re-
duction observed by Dodd et al. [8] only applies to women
with a previous history of PTB and could not be seen in
subgroup analyses for women with multiple pregnancies
or other reasons for ‘PTB risk’. Two interventions for
women with (high) risk of developing pre-eclampsia re-
duced PTB risk, but also showed a positive impact on
other pregnancy outcomes: These interventions are the
administration of low-dose aspirin after 12 weeks of gesta-
tion [37] and calcium supplementation [35], though the
latter intervention simultaneously led to a small increase
in the risk of HELLP syndrome. Based on subgroup ana-
lyses in this review, the recommendation for calcium sup-
plementation also applies to women with low dietary
calcium intake [35], while no positive effects could be ob-
served in the separate review on calcium supplementation
during pregnancy in the general population [42]. Positive
effects on PTB in undernourished women or women from
low-income countries with high perinatal mortality can be
expected for nutritional advice to increase protein and en-
ergy intake, balanced energy and protein supplementation
[43], as well as zinc supplementation [47].
Interventions without a significant effect on PTB risk
The remaining antenatal interventions had no (statisti-
cally significant) effect on our primary outcome of
PTBs < 37 weeks. However, a few interventions showed
at least advantages in secondary outcomes: nutritional
supplements like fish oil [51] led to a reduction in early
PTBs, balanced protein/energy supplementation [43] to
fewer SGA babies and stillbirths, and multiple micronu-
trients [50] to fewer LBW and SGA babies. Drugs, e.g.,
antibiotic treatment, reduced the number of LBW babies
in women with asymptomatic bacteriuria [27], and with
heparin treatment, fewer SGA babies were observed inwomen considered at risk of placental dysfunction [57].
Conversely, some interventions increased the risk of nega-
tive effects in secondary outcomes without influencing
PTB rates. Increased side effects were observed for daily
iron supplementation [49], (any) vitamins in women ir-
respective of risk of miscarriage [13], (any) antioxidants
[34], diuretics [31], as well as for nitric oxide [30] in pre-
eclampsia prevention. More SGA babies could be observed
when beta-blockers were used in women with mild to
moderate hypertension [38], but also for the use of high
protein supplementation in pregnancy [43]. Finally, the re-
duction in the number of antenatal visits [55] led to more
miscarriages/ perinatal deaths. About half of the included
reviews were not able to detect any statistically significant
group difference in primary or secondary outcomes.
However, some of these interventions might show posi-
tive or negative effects in outcomes not covered in this
overview (e.g., additional support during pregnancy re-
duced the likelihood of caesarean births or antenatal
hospital admissions [53]).
Interventions with unknown influence on PTB risk
As an unintended result of this overview, during the lit-
erature selection process we discovered 28 Cochrane re-
views which intended to report on PTB < 37, but were
not able to find any RCTs reporting PTB < 37 data.
These reviews addressed highly relevant and sometimes
routinely used interventions like cervical pessary for pre-
vention [64] or risk scoring systems for predicting PTB
[65], routine ultrasound in early pregnancy [66], or diet-
ary advice for the prevention of [67] and screening for
[68] gestational diabetes. In order to provide some infor-
mation about potential effects on secondary outcomes
considered in this overview, we prepared Table S4 as an
additional file ([see Additional file 5]).
Results against the backdrop of prior research
Compared to the overview of interventions which might in-
fluence PTB risk, published in 2008 [5], minimal changes
in the conclusions can be observed. The elevated PTB risk
of metronidazole was already reported in 2008, and vitamin
C supplementation (though in combination with vitamin E
for pre-eclampsia prevention) was reported to be ineffective
with regard to PTB rates (but not increasing them). Con-
flicting results of antibiotic and progesterone treatment had
already been stated. The beneficial effects of smoking cessa-
tion and of low-dose aspirin for women at high risk of de-
veloping pre-eclampsia were already known. Regarding
cerclage, Iams et al. [5] had already reported beneficial ef-
fects only for subgroups of pregnant women (e.g., with a
short cervix and a history of PTB). Contrary to the findings
of our overview, fetal fibronectin testing (with subsequent
metronidazole and erythromycin treatment) was considered
to be ineffective, bed rest had not been studied and
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for calcium supplementation, nor for protein and calorie
supplementation. Effects of magnesium or zinc supplemen-
tation, oestrogen or levothyroxine treatment had not been
mentioned in the article [5] as a primary or secondary pre-
ventive measure. The two remaining interventions judged
as promising in 2008 [5] did not show a significant effect
on our primary outcome, but fish oil led to a reduction in
early PTBs in women without pre-eclampsia/IUGR, and
antibiotic treatment reduced the number of LBW babies in
women with asymptomatic bacteriuria.
In the recently published article by Requejo et al. [69]
(based on the WHO Born Too Soon-Global Action Report
on Preterm Birth [1]), recommendations for antenatal care
have been summarised. The authors state that screening
and treatment for asymptomatic bacteriuria or bacterial
vaginosis ‘may reduce PTBs’, but add that study findings
show inconsistent results and therefore urge more re-
search on the relationship between infections and PTB in
general. Similarly, they point out that providers might ad-
minister nutritional supplements and counselling services,
but again refer to the lack of clear beneficial effects shown
in clinical trials, especially with regard to the timing of nu-
tritional interventions. They emphasise the need for iden-
tifying women at higher risk of PTB, but declare that
prospective studies to evaluate risk-screening tools are still
needed. According to the authors, this also applies to spe-
cialised antenatal clinics for at-risk women, for which evi-
dence of ineffectiveness is based on (older) trials with less
comprehensive screening tests. Requejo et al. [69] further
confirm the positive findings on progesterone application
for defined subgroups of women (singleton pregnancies
with short cervix). They also state that small reductions
in PTB rates have been reported in Cochrane reviews
for treatment of pre-eclampsia (e.g., for calcium supple-
mentation) and that further research is needed for cervical
pessary application and cerclage in different subpopula-
tions of women.
Overall, they conclude that ‘clinical trial literature shows
a lack of evidence for many of the preventive interventions
currently in use’ and explain the paucity of evidence as
partly being due to insufficient research on underlying de-
terminants of preterm delivery.
Strengths and weaknesses of the study
This article is, to our knowledge, the first overview of
Cochrane reviews on interventions to reduce PTB rates.
The prevention of spontaneous preterm birth appears to
be a rapidly evolving maternal and child health topic. 21
of the included reviews were published or updated be-
tween 2010 and 2012. Two protocols for reviews directly
targeted at PTB prevention (cerclage in multiple preg-
nancies [70] and the treatment of periodontal disease
[71]) were registered in the Cochrane Library at the timeof our literature search. Therefore, underlying evidence
might have even changed in the time period between the
literature search and publication of this overview. In-
cluded Cochrane reviews show a wide-ranging publish-
ing period of the underlying primary research. It should
be questioned whether results from studies conducted in
the 1930s (e.g., on vitamin A supplementation in preg-
nancy [44]) are transferable to pregnant women in the
21st century at all.
We decided to restrict our overview of reviews solely
to Cochrane systematic reviews. Conclusions from this
overview therefore only apply to results from Cochrane
reviews. We acknowledge that there are other systematic
reviews that might be more recent, cover other interven-
tions not targeted by Cochrane reviews so far, or even
came to differing conclusions based on different inclu-
sion criteria of primary research.
We prepared this overview mainly in accordance with
the corresponding methods chapter of the Cochrane
Handbook of Systematic Reviews of Interventions (Chapter
22) [6], but we modified, e.g., the presentation of results
by deciding to present forest plots for the primary out-
come, or by only distinguishing between statistically sig-
nificant changes – visualised by arrows (Table S3 [see
Additional file 4]) – without presenting effect estimations
with confidence intervals or other data for our secondary
outcomes.
Results of an overview of reviews are influenced by the
methodological quality of included systematic reviews.
The aggregation of data from different primary studies
in systematic reviews may lead to diverging results of
the reviews. Similarly, the inclusion of different system-
atic reviews in an overview of reviews is likely to cause
inconsistent results across overviews, depending on the
underlying, already aggregated evidence considered. We
justified our refraining from a quality assessment of in-
cluded systematic reviews by referring to quality stan-
dards for the preparation of Cochrane reviews defined
by the Cochrane collaboration [6]. According to these
requirements, Cochrane reviews should fulfil adequate
quality standards [72] for the domains judged as import-
ant within AMSTAR, a validated tool to assess the meth-
odological quality of systematic reviews [73]. These
criteria include an a priori definition of the research
question and inclusion criteria, a duplicate study selec-
tion and data extraction, a comprehensive literature
search including grey literature, the provision of the
characteristics of included studies and a list of excluded
studies, a quality assessment of included studies and its
appropriate consideration in formulating conclusions,
the appropriateness of statistical methods used, the as-
sessment of a potential publication bias and, finally, the
declaration of potential conflicts of interest. We further
decided not to perform a quantitative meta-analysis to
Piso et al. BMC Research Notes 2014, 7:265 Page 8 of 10
http://www.biomedcentral.com/1756-0500/7/265estimate a pooled effect size of results because of the ob-
vious heterogeneity of interventions. This predefinition
avoided an overestimation of (pooled) effects, given the
risk that data from primary studies might have already
been included in several reviews. However, we only ex-
cluded one Cochrane review [63] that was solely based
on RCTs included in a more recent review [7]. Other in-
cluded systematic reviews might overlap with regard to
included RCTs.
In general, an evident drawback of an overview of re-
views is the loss of more detailed information by qualita-
tively aggregating information on a meta-level. For
example, women ‘at (high) risk of PTB’ were defined
precisely by some Cochrane review authors, while others
referred to the trials authors’ definitions, women’s obste-
tricians judgement or did not specify risk evaluation at
all. Drawing general conclusions from the results of an
overview is therefore difficult and would be negligent
without taking a closer look at individual reviews, in-
cluded primary research, and contradictory results of
subgroup analyses performed.
Conclusion
The possible effects of a diverse range of interventions
on PTB have been evaluated in Cochrane systematic re-
views. Few interventions have been demonstrated to be
effective and a small number have been found to be
harmful. For around half of the interventions evaluated,
the Cochrane review concluded that there was insuffi-
cient evidence to provide sound recommendations for
clinical practice. No RCT evidence is available for a
number of potentially relevant interventions.
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